WHAT WE OFFER: PERSONALISED TESTING
Maintrac is an innovative analysis platform in cancer diagnostics and therapy monitoring. Maintrac identifies and quantifies the circulating tumour cells in the blood sample of cancer patients and analyses the efficacy of selected drugs. In clinical trials with more than 900 patients, Maintrac has demonstrated that monitoring circulating tumour cells in the adjuvant situation, during maintenance and antibody therapy has significant benefits, including earlier detection of possible relapse.
Escapee cancer cells in the blood, or 'CTCs' as they are known, can be found by a simple blood test. A CTC Count test finds existing escapee cancer cells (CTCs) in a blood sample and counts them. Monitoring changes in cancer activity over time is made easy with this test... To learn more, please visit our patient or practitioner information page.
Some CTCs can hide in the blood stream for months or years before activating and forming a second tumour. Some CTCs may even resist treatment. This test analyses how a person's CTCs respond when exposed to a recommended chemotherapy regimen or botanical treatment. To learn more, please visit our patient or practitioner information page.
Biomarker analysis can be used to identify receptors that are targets for treatment, to assess the potential for cancer spread or to assist in diagnosis. The identification of certain receptors on a person's CTCs may help practitioners design personalised treatment strategies... To learn more, please visit our patient or practitioner information page.
Tumour Sphere Units tests to see if a person's CTCs can multiply to form microscopic clusters, called Tumour Sphere Units, in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis. To learn more, please visit our patient or practitioner information page.
Biological age: We analyze your biological age by innovatively using the combination of epigenetic and telomere markers in a drop of blood.
Health + Prevention: An individualized concept for your healthy aging. For the first time, we analyze the combination of epigenetic and telomere markers together with inflammation and DNA stability markers from a drop of blood.
Metabolic health: HealthBioCare analyses as first company not only genetic but also epigenetic characteristics which change due to nutrition and life style. The use of these epigenetic markers allows to monitore results of improved nutrition and lifestyle. The results of the analysis give also advice for your recommended way of sport, skin care and health prevention. For more information, please visit the Healthbiocare website
exacta® is a comprehensive in depth tumour gene expression analysis performed by Datar Cancer Genetics.
Datar Cancer Genetics is a World-leading molecular oncology facility with a fully equipped laboratory, integrated process platforms, in-house bioinformatics team, and a huge genetic data base for precise and updated reporting.
exacta® helps unravel the driver mutations and pathways that are propelling a particular person’s cancer through multi-analyte and multi-coordinate analysis over 20.805 genes in the cancer genome. This analysis helps identify targeted drugs that would be most effective for a particular cancer. exacta®, thus enables a highly sophisticated treatment strategy beyond conventional perspective, even for difficult cancers.
Click here to learn more.